Get the Stockscreener App
341.64
3.47%
11.47
After Hours:
340.01
-1.63
-0.48%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $341.64, with a volume of 3.60M.
It is up +3.47% in the last 24 hours and up +3.56% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$330.17
Open:
$332.1
24h Volume:
3.60M
Relative Volume:
1.39
Market Cap:
$183.97B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
26.41
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
+4.38%
1M Performance:
+3.56%
6M Performance:
+16.62%
1Y Performance:
+30.37%
1-Day Range:
$332.10
$343.05
1-Week Range:
$318.21
$343.05
52-Week Range:
$259.82
$346.38
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
341.64 | 177.79B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,108.09 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.49 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.42 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.98 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.60 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - PR Newswire
Amgen Inc.: How a Biotech Veteran Is Re?Engineering Its Own Future - AD HOC NEWS
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs - Benzinga
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial - TipRanks
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline - Finviz
UBS Raises Amgen (AMGN) Price Target to $380 and Upgrades to Buy - GuruFocus
Amgen acquires cancer drugmaker Dark Blue Therapeutics for up to $840 mn - ETPharma.com
Amgen buys Dark Blue Therapeutics in $840m oncology deal - Yahoo Finance
UBS assumes coverage on Amgen stock with Buy rating, $380 price target - Investing.com UK
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 - simplywall.st
Cerity Partners LLC Sells 6,837 Shares of Amgen Inc. $AMGN - MarketBeat
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies - GlobeNewswire Inc.
CWA Asset Management Group LLC Sells 14,786 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Acquires Dark Blue in $840 Million Deal to Pursue Innovative Leukemia Treatments - Bitget
Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report - BioCentury
UBS Upgrades Amgen (AMGN) to Buy, Raises Price Target to $380 - GuruFocus
Amgen upgraded to buy at UBS on potential of MariTide, olpasiran - Seeking Alpha
Amgen Paints Pipeline Dark Blue In Acquisition of Small Molecule Developer - Citeline News & Insights
Amgen’s Own High Court Loss Cited in Pushback to Evenity Claims - Bloomberg Law News
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal - GuruFocus
Amgen swoops on UK cancer biotech in deal worth up to $840mn - Financial Times
Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive
$840 million Dark Blue buy hands Amgen AML drug - The Pharma Letter
Amgen buys UK biotech Dark Blue Therapeutics for up to $840m - Sharecast.com
Amgen to buy blood cancer biotech Dark Blue Therapeutics in $840M deal - Axios
Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - marketscreener.com
Amgen adds preclinical cancer asset via $840M deal for Dark Blue Therapeutics - FirstWord Pharma
Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million - marketscreener.com
Amgen (AMGN) Acquires Dark Blue Therapeutics for $840 Million - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million - Investing.com
Dark Blue Therapeutics acquired by Amgen for up to $840 million - marketscreener.com
Amgen (AMGN) Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million By Investing.com - Investing.com Canada
Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal - Nasdaq
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE - PR Newswire
Amgen Buys Cancer Drug Developer Dark Blue in $840 Million Deal - Bloomberg.com
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease - BioSpace
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Amgen's Q4 2025 Earnings Report - Barchart.com
Commonwealth Equity Services LLC Has $105.58 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News
D.A. Davidson & CO. Purchases 6,222 Shares of Amgen Inc. $AMGN - MarketBeat
Greenspring Advisors LLC Makes New $1.69 Million Investment in Amgen Inc. $AMGN - MarketBeat
AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug - BioSpace
Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus - Yahoo Finance
Railway Pension Investments Ltd Has $27.18 Million Position in Amgen Inc. $AMGN - MarketBeat
Daymark Wealth Partners LLC Has $43.01 Million Holdings in Amgen Inc. $AMGN - MarketBeat
With 80% Ownership, Amgen Inc. (NASDAQ:AMGN) Boasts of Strong Institutional Backing - 富途牛牛
Asset Management One Co. Ltd. Buys 9,753 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
2.46%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):